The case for & against
Bull & Bear analysis
Bullish
Aurora Cannabis Inc. (NASDAQ: ACB) is a leading global player in the medical cannabis sector, specializing in high-quality cannabis products for medical applications. The company operates GMP-certified facilities in Canada and Germany, focusing primarily on the burgeoning medical cannabis markets in established regions such as Australia, Poland, Germany, and the UK. Aurora's strategic emphasis on high-margin products positions it advantageously within a rapidly growing $9 billion market for medical cannabis.
Bull says
- ↑Q4 net revenue of $321 M (+11% YoY) driven by 10% global medical growth
- ↑Adjusted gross margin at 64%; adjusted EBITDA rose 32% to $54 M
- ↑International medical revenue up 17%, now 64% of total sales
- ↑$165 M cash with zero debt funds Safari Flower acquisition
- ↑FY27 global medical cannabis revenue guided to $269–281 M
- ↑High growth potential and strong cash position support expansion
Bear says
- ↓Canadian medical reimbursement rates slashed 30%, hitting domestic revenue
- ↓Heightened competition in Germany’s value segment pressures pricing
- ↓Exit from lower-margin consumer segment risks long-term engagement
- ↓Stock volatility risk high, indicating potential for sharp swings
- ↓Analyst earnings revisions trending down amid profitability concerns
- ↓Weak factor scores: low earnings yield, deteriorating balance sheet, high short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 08-15-2026neutral
Transcript signals
Bull points
- we expect it to continue to be positive at the adjusted EBITDA, and we expect it to grow versus the current quarter.
- We're executing our strategy within global medical cannabis and delivering strong results through sustained profitable growth.
- Our financial performance demonstrates Aurora's differentiated platform that is supported by a strong and flexible balance sheet.
Bear points
- the Bevo liabilities look like they moved to current, which appears to be related to a covenant breach for not providing audited financials.
- Consumer cannabis net revenue was $7.9 million, down from $11.5 million. The year-over-year change was the expected result of our continued decisions to focus on portfolio optimization and prioritize sales to our higher-margin medical cannabis business.
- Adjusted gross margin from plant propagation revenue was 6% compared to 18% in the year-ago period. The decrease was related to inventory write-off caused by a non-recurring quality issue, as well as some surplus crops that were not sold. Excluding these non-recurring costs, adjusted gross margin before fair value adjustments would have been more in line with historical trends.
Read full transcript analysis ›